Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study
- 1 May 2004
- journal article
- Published by Elsevier in The Lancet
- Vol. 363 (9423) , 1768-1771
- https://doi.org/10.1016/s0140-6736(04)16302-2
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Anti-Erythropoietin Antibodies and Pure Red Cell AplasiaJournal of the American Society of Nephrology, 2004
- Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than anotherCurrent Medical Research and Opinion, 2004
- Pure red-cell aplasia due to anti-erythropoietin antibodiesNephrology Dialysis Transplantation, 2003
- Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapyAmerican Journal of Kidney Diseases, 2003
- Benefits of recombinant human erythropoietin.The Lancet, 2002
- Immunogenicity of therapeutic proteins: Clinical implications and future prospectsPublished by Elsevier ,2002
- Antibodies against rHuEPO: native and recombinant.Nephrology Dialysis Transplantation, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Drug-Induced Autoimmune Red-Cell AplasiaNew England Journal of Medicine, 2002
- Erythropoietin and anemiaSeminars in Nephrology, 2001